Exploratory IND Guidance Emphasizes FDA Flexibility On Data Requirements
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency believes that industry has not taken full advantage of the flexibility provided in investigational new drug regulations. The draft guidance advises sponsors on how to proceed with early Phase I, short-term "microdosing" studies.
You may also be interested in...
Phase 0.5? FDA Guidance Allows Pre-Clinical Micro-Dose Studies In Human Subjects
Aimed at academic researchers, FDA's final guidance permits study of the mechanism of action of new agents at low doses.
Phase 0.5? FDA Guidance Allows Pre-Clinical Micro-Dose Studies In Human Subjects
Aimed at academic researchers, FDA's final guidance permits study of the mechanism of action of new agents at low doses.
Radioactive Drugs Research Comment Period Reopened By FDA
The agency will accept comments for 60 days on its regulation of radioactive drugs for certain research uses. The additional comment period will allow for feedback in the context of a draft guidance on exploratory INDs released in April, FDA says.